Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + trastuzumab + nab-paclitaxel as neoadjuvant therapy for stage II–III HER2-positive breast cancer
ChiCTR2200056592Phase 4Recruiting
- Sponsor
- Mudanjiang Cancer Hospital
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pyrotinib, trastuzumab and nab-paclitaxel in breast cancer, sponsored by Mudanjiang Cancer Hospital. Primary endpoint: pathological complete response rate. Started Dec 2020; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200056592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056592.